IMCR - Immunocore Holdings plc
After hours:
Chart Events
Slow Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 56.67 |
| Open | 56.59 |
| Bid | 54.95 x 800 |
| Ask | 62.02 x 800 |
| Day's Range | 55.79 - 57.23 |
| 52 Week Range | 26.12 - 69.06 |
| Volume | |
| Avg. Volume | 263,832 |
| Market Cap | 2.644B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.10 |
| Earnings Date | May 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.88 |
Fair Value
Related Research
- Financial Times
Why companies don’t want to list in the UK any more
Immunocore got its start in Bell’s lab more than 20 years ago, but as the company grew, they needed to find investors. But after that series A round when it came time to raise more money, funding in the UK dried up.
Simply Wall St.Immunocore Holdings First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Immunocore Holdings ( NASDAQ:IMCR ) First Quarter 2023 Results Key Financial Results Revenue: UK£44.5m (up 98% from 1Q...
GlobeNewswireImmunocore Reports First Quarter 2023 Financial Results and Provides Business Update
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £42.1 million ($52.0 million) in Q1 2023, with continued commercial expansion Randomization started in Phase 2/3 trial with KIMMTRAK in previously-treated, advanced melanoma Patients continue to enroll in monotherapy and combination arms of IMC-F106C (PRAME-HLA-A02) Phase 1/2 trial Enrolling people living with HIV in multiple ascending dose part of IMC-M113V Phase 1 trial Cash and cash e
- GlobeNewswire
Immunocore to present at the Bank of America Securities 2023 Health Care Conference
Immunocore to present at the Bank of America Securities 2023 Health Care Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 May 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at th
- GlobeNewswire
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated with longer overall survival (OS) Median 46 months follow up from Phase 2 trial confirms median OS of 16.8 months, with landmark OS rates approximately double historical rates in metastatic uveal melanoma population (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 18 April 2023) Immunoco
PR NewswireGrey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023
Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced the presentation of new preclinical data on the company's potential first-in-class inhibitors of ERAP1 at the American Association of Cancer Research (AACR) Annual Meeting 2023. Presented data highlighted the ability of the company's ERAP1 inhibitors to generate and upregulate cancer antigens, creating novel therapeutic tar
- Simply Wall St.
Immunocore Holdings plc's (NASDAQ:IMCR) Share Price Not Quite Adding Up
With a price-to-sales (or "P/S") ratio of 14.8x Immunocore Holdings plc ( NASDAQ:IMCR ) may be sending bearish signals...
- GlobeNewswire
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 April 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the 2
ZacksImmunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $48.54, marking a -1.74% move from the previous day.
ZacksImmunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $47.52, moving -0.71% from the previous trading session.
ZacksImmunocore Holdings PLC Sponsored ADR (IMCR) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Immunocore Holdings PLC Sponsored ADR (IMCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Insider MonkeyTop 10 Growth Stocks in Biotech
In this article, we will discuss the Top 10 Growth Stocks in Biotech. You can skip our industry overview and go directly to the Top 5 Growth Stocks in Biotech. The biotech industry encompasses a wide range of fields, including genetic engineering, biomanufacturing, bioinformatics, and synthetic biology. It has the potential to transform many aspects […]
ZacksImmunocore Holdings PLC Sponsored ADR (IMCR) Gains But Lags Market: What You Should Know
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $53.51, moving +1.61% from the previous trading session.
ZacksImmunocore Holdings PLC Sponsored ADR (IMCR) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.
- GlobeNewswire
Immunocore to present four posters at AACR Annual Meeting 2023
Immunocore to present four posters at AACR Annual Meeting 2023 Updated three-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing early ctDNA reduction on tebentafusp-tebn associated with better overall survival in previously untreated metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 14 March 2023) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage bi
Insider MonkeyImmunocore Holdings plc (NASDAQ:IMCR) Q4 2022 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Greetings. Welcome to the Immunocore 2022 Financial Results and Business Update Call. Please note, this conference is being recorded. I will now turn the conference over to your host, Clayton Robertson, Head of Investor Relations. Thank you. You may begin. Clayton Robertson: […]
- Thomson Reuters StreetEvents
Q4 2022 Immunocore Holdings PLC Earnings Call
Q4 2022 Immunocore Holdings PLC Earnings Call
- GlobeNewswire
Immunocore Reports 2022 Financial Results and Provides Business Update
Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £42 million ($51 million) in Q4 2022 and £117 million ($141 million) in 2022; approved in over 30 countries and nearly 200 patients on global early access program Enrolling IMC-F106C (PRAME-HLA-A02) in monotherapy and combination arms of Phase 1/2 clinical trial and expanding PRAME franchise, including first-in-class PRAME-HLA-A24 target and a PRAME HLA-A02 half-life extension IND planne
ZacksIs a Surprise Coming for Immunocore (IMCR) This Earnings Season?
Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- GlobeNewswire
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following upcoming investor conf
ZacksImmunocore (IMCR) to Report Q4 Earnings: What's in the Cards?
On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.
ZacksInvestors Heavily Search Immunocore Holdings PLC Sponsored ADR (IMCR): Here is What You Need to Know
Immunocore Holdings PLC Sponsored ADR (IMCR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- GlobeNewswire
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 February, 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced that it will report full yea
BenzingaImmunocore Reveals First Data From HIV Infection Candidate Study
Immunocore Holdings plc (NASDAQ: IMCR) has presented the first safety and activity data with IMC-M113V, a bispecific soluble TCR therapy built on its ImmTAX technology for the treatment of people living with HIV. The data were presented at the Conference on Retroviruses and Opportunistic Infection. In the single ascending dose part of the trial, three dose levels of IMC-M113V were given as a single IV infusion. All doses were well tolerated. There were no serious adverse events, significant chan
- GlobeNewswire
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial shows IMC-M113V is well tolerated Expected markers of T cell activation observed in half of participants at 15-mcg dose; plasma viral load remained suppressed throughout dosing and follow-up The multiple ascending dose part of the trial is enrolling participants to identify safety and anti-viral activ